Where can I find news about REC.MI?

The latest press releases, SEC filings, and earnings call transcripts for Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.

Where are REC.MI's SEC filings?

Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

When was REC.MI's last earnings call?

The most recent earnings call transcript for Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

REC.MI

Recordati Industria Chimica e Farmaceutica S.p.A.

MIL·Medical, Pharmaceuticals · Healthcare

€51.35€0.05−0.10%

Market cap€10.45B·Market closed·Jul 23 8:24 AM UTC

Press Releases

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%
Consolidated net revenue of € 713. 4 million in the first quarter of 2026,4. 9% or8. 7% on a like-for-like basis(3) at constant exchange rates (CER); adverse FX impact of € 29. 1 million (-4.
globenewswire.comMay 12, 2026 · 12:46 PM
RECORDATI: IL FORTE SLANCIO DEL GRUPPO PROSEGUE NEL PRIMO TRIMESTRE DEL 2026 RICAVI NETTI +4,9%, EBITDA(1) +5,0%, UTILE NETTO RETTIFICATO(2) +7,2%
Ricavi netti consolidati nel primo trimestre del 2026 pari a € 713,4 milioni,4,9% o8,7% a perimetro omogeneo(3) e a cambi costanti; impatto negativo dei cambi di € 29,1 milioni (-4,3%)EBITDA(1) pari a € 283,6 milioni,5,0%, con un'incidenza sui ricavi netti del 39,7%Utile netto rettificato(2) pari a € 188,1 milioni,7,2%, con un'incidenza sui ricavi netti del 26,4%Utile netto pari a € 153,1 milioni,22,4% Free cash flow(4) pari a € 92,1 milioni, -€ 66,7 milioni rispetto all'anno precedenteDebito netto(5) pari a € 1.
globenewswire.comMay 12, 2026 · 12:46 PM
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
RECORDATI FIRST NINE MONTHS 2025 RESULTS:REVENUE12. 2%, EBITDA(1)11. 8%, ADJUSTED NET INCOME(2)10. 7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1. 2 BILLION Consolidated net revenue of € 1,956.
globenewswire.comNov 11, 2025 · 2:27 PM

SEC Filings

No recent filings indexed.

Transcripts

PRO

Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.

Click below to see what's inside, then upgrade to read every transcript for REC.MI and 80,000+ other tickers.

Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.

Frequently Asked Questions About REC.MI

Where can I find news about REC.MI?: The latest press releases, SEC filings, and earnings call transcripts for Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.
Where are REC.MI's SEC filings?: Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
When was REC.MI's last earnings call?: The most recent earnings call transcript for Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

Recordati Industria Chimica e Farmaceutica S.p.A.

Frequently Asked Questions About REC.MI

Recordati Industria Chimica e Farmaceutica S.p.A.

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: IL FORTE SLANCIO DEL GRUPPO PROSEGUE NEL PRIMO TRIMESTRE DEL 2026 RICAVI NETTI +4,9%, EBITDA(1) +5,0%, UTILE NETTO RETTIFICATO(2) +7,2%

RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION

Frequently Asked Questions About REC.MI

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: IL FORTE SLANCIO DEL GRUPPO PROSEGUE NEL PRIMO TRIMESTRE DEL 2026 RICAVI NETTI +4,9%, EBITDA(1) +5,0%, UTILE NETTO RETTIFICATO(2) +7,2%

RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION